Janus Henderson Global Life Sciences Webinar

Tuesday 24th November – 3pm GMT/4pm CET

Pfizer and BioNTech have announced preliminary data from a late-stage clinical trial for their COVID-19 vaccine candidate, and the results were better than expected.
Andy Acker, Portfolio Manager and Augustin Mohedas Research Analyst will explain what this means for the fight to end the pandemic and the next leg of the market cycle.

They will also provide an update on the Global Life Sciences and Biotech Strategy including:

  • Fund performance: key contributors and manager outlook
  • Investment process and team update
  • Why healthcare now?

Futured Speakers: 

Moderator:

  • Federico Pons, Country Head Italy

Register

{{responseDataText}}

{{responseDataText}}

Speakers

Andy Acker

Andy Acker

CFA, Portfolio Manager

Andy Acker is a Portfolio Manager at Janus Henderson Investors responsible for managing the Global Life Sciences and Biotechnology strategies since 2007 and 2018, respectively. He also leads the firm’s Health Care Sector Research Team. Andy was assistant portfolio manager on the Global Life Sciences strategy from 2003 to 2007. He joined Janus in 1999 as a research analyst focused on companies in the biotechnology and pharmaceutical industries. Prior to this, he worked as a strategy consultant for the Boston Consulting Group and as a health care analyst for Morgan Stanley Venture Partners.

leggi

Andy received his bachelor of science degree in biochemical sciences from Harvard University, graduating magna cum laude and Phi Beta Kappa. He also earned an MBA with honours from Harvard Business School. Andy holds the Chartered Financial Analyst designation and has 24 years of financial industry experience.

Agustin Mohedas

Agustin Mohedas

Ph.D. Research Analyst

Agustin Mohedas, Ph.D. is a Research Analyst at Janus Henderson Investors focused primarily on stocks in the biotechnology sector, a position he has held since 2019. Before joining the firm, Dr. Mohedas was a senior analyst at Eventide Asset Management, working on the Healthcare and Life Sciences Fund from 2017. Prior to this, he was an analyst with RA Capital Management, a long/short hedge fund focused on biotechnology, from 2014.

leggi

Dr. Mohedas received his bachelor of science degree in biomedical engineering from Texas A&M University, graduating summa cum laude. He also earned a Ph.D. in medical engineering and medical physics from the Harvard-MIT Program in Health Sciences and Technology. His Ph.D. research focused on drug development for a rare genetic disease, resulting in multiple patents and publications. He has 6 years of financial industry experience.

Add to calendar

  Add to calendar
This site uses cookies to provide you with a personalized experience. By continuing to browse, you accept the use of cookies.